Guardian Bio

Guardian Bio is pioneering a novel approach to cancer therapy by harnessing the power of the patient's own immune system. The immune system serves as the body's primary defense against cancer, and its failure often precedes the development of advanced disease. Dendritic cells, critical components of the immune system, orchestrate immune responses. Research indicates that dendritic cell dysfunction is prevalent in cancer patients, hindering the effectiveness of other therapies.

Guardian Bio's platform focuses on developing a dendritic cell-based product designed to stimulate anti-tumor activity. This is achieved by activating the immune system's cytotoxic cells and educating them to target multiple cancer antigens. The process involves extracting stem cells from cancer patients, differentiating them into therapeutic dendritic cells specifically tailored to recognize the patient's tumor, and then reintroducing these cells back into the body.

These therapeutic dendritic cells aim to reinvigorate the immune system's cytotoxic cells, providing them with the necessary impetus to effectively combat cancer.